Page 1

3rd Quarter 2026 Results 3rd Quarter 2026 Sales $ 25.4B Worldwide increased ▲ 5.9 % Diluted earnings per share ( EPS ) 3 $ 0.09 Includes the impact of one - time special charges and M & A transactions Excluding the impact of translational currency Worldwide increased 6.0 % 1 Stelara impacted results by ~ ( 420 ) basis points Adjusted diluted earnings per share¹ , 4 Worldwide decreased $ 2.59 ( 7.5 ) % www Joaquin Duato Chairman & Chief Executive Officer Johnson & Johnson 66 Johnson & Johnson's strong third - quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio . In the third quarter , we advanced breakthroughs that will redefine care for patients , from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma . This progress , together with strategic investments in high - growth areas , gives us clearer line of sight to double - digit growth by the end of the decade . " Johnson & Johnson $ 16.8 Worldwide Innovative Medicine sales billion Innovative Medicine worldwide reported sales increased 7.7 % or 7.9 % operationally² . Stelara impacted results2 by ~ ( 690 ) basis points . Primary operational drivers : $ 8.6 billion Tremfya ( guselkumab ) Spravato ( esketamine ) C nasal spray DARZALEX ( daratumumab ) Worldwide MedTech sales MedTech worldwide sales increased 2.5 % reported and operationally² . Primary operational drivers : CARVYKTI ( ciltacabtagene autoleucel ) Electrophysiology Trauma Shockwave CAPLYTAY ( lumateperone ) capsules TECVAYLI ( teclistamab - cayv ) RYBREVANT + ( amivantamab - vmjw ) on for N U30 / 70 ] LAZCLUZE ™ ( lazertinib ) Erleada ( apalutamide ) 200gable Contact Lenses Surgical Vision Biosurgery For full financial data , non - GAAP reconciliations and cautionary statements , please refer to Johnson & Johnson's earnings release issued on October 13 , 2026 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx 1 Non - GAAP financial measure ; non - GAAP financial measures should not be considered replacements for , and should be read together with , the most comparable GAAP financial measures . 2 Non - GAAP measure ; excludes the impact of translational currency . 3 Includes the impact of a one - time special charge related to the proposed talc litigation resolution , as well as expenses related to the acquisition of Firefly Bio , Inc. and strategic collaboration with Sail Biomedicines 4 Includes expenses related to the acquisition of Firefly Bio , Inc. and strategic collaboration with Sail Biomedicines Note : Values may be rounded Caution Concerning Forward - Looking Statements : This document contains " forward - looking statements " as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance . You are cautioned not to rely on these forward - looking statements , which are based on current expectations of future events . For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions , expectations , and projections expressed in any forward - looking statements , review the " Note to Investors Concerning Forward - Looking Statements " included in the Johnson & Johnson earnings release issued on October 13 , 2026 as well as the most recently filed Johnson & Johnson Reports on Forms 10 - K and 10 - Q . Johnson & Johnson does not undertake to update any forward - looking statement as a result of new information or future events or developments .